NVSR, BEDA, HTDS, UNDT, TPTX, MODC Stocks to Watch for Wednesday, July 29th from OTCPicks.com
Our Stocks to Watch tomorrow include NavStar Technologies Inc. (OTC: NVSR), Bederra Corp. (OTC: BEDA), Hard to Treat Diseases Inc. (OTC: HTDS), Universal Detection Technology (OTCBB: UNDT), TorreyPines Therapeutics Inc. (Nasdaq: TPTX) and Modern Technology Corp. (OTC: MODC).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
"Up 74.12% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
July 28 - NavStar Field Testing a Great Success in
NavStar Reports Successful Field Test, as Conducted by Fixed Equipment S.A., and Government Purchase Order Is Weeks Away
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo with specific geographic focus in Latin America, today announced that the field trial in Ecuador has entered the final stages and will result in the execution of a Purchase Order for 4,033 units worth $732,000.
After several months and many hours of testing, the field trial with the public transportation system in
"With 25 units involved in the field trial we have stressed the system at all its critical points and it has proven itself extremely reliable and flexible and we are down to a few very minor software issues," said Roberto Manosalvas, General Manager, Fixed Equipment S.A. "NavStar's high quality device and technical support and our 'hands-on everyday' availability have been the deciding factor in winning this business."
"We are pleased that the field testing in
BEDERRA CORPORATION (OTC: BEDA)
"Up 135.29% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/BEDA.php
Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater
BEDA News:
July 14 - Bederra Corporation Signs Letter of Intent to Acquire Neogenex Medical Technologies, Inc.
Bederra Corporation (OTC: BEDA), a medical imaging and diagnostic Company, has signed a Letter of Intent to acquire Neogenex Medical Technologies, a Houston, TX based Technology, Development and Marketing company that focuses on Pain Therapies for Arthritis, Soft tissue and Joint applications.
Neogenex Medical Technologies, Inc. has rights to patents and technology to produce and market a low level laser device cleared by the FDA to treat arthritis pain and carpal tunnel syndrome. The company currently markets these FDA approved devices to medical professionals, Fitness Clubs and Corporate Wellness Facilities. More than 3500 medical professionals, therapists and trainers are currently using these devices as treatment options.
"The current market for these products and treatments is well over $10-15 Billion as more than 80 million people can utilize these therapies. Neogenex has already established itself in this market and would make a great addition to Bederra's growing line of products and services," stated Graham Williams, CEO of Bederra.
HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)
"Up 112.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php
In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.
HTDS News:
July 28 - Hard to Treat Diseases To Re-Release European TV Segment In North America For Potential Treatment Of MS
Hard to Treat Diseases, Inc. (OTC: HTDS) Slavica Bio Chem Division (Slavica) intends to re-release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and www.htdsmedical.com. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.
In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the
Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division). This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.
Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from
In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in
The company intends to provide many updates on the work and HTDS activities on a timely basis.
UNIVERSAL DETECTION TECHNOLOGY (OTCBB: UNDT)
"Up 312.50% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/UNDT.php
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
UNDT News:
July 28 - Universal Detection Technology Receives
Patent is the Second for the Company's Licensed Bioterrorism Detection Invention
Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it has been granted a patent from the U.S. Patent and Trademark Office (USPTO) for its automated airborne anthrax detection system. The patent is the company's second for technology licensed by the California Institute of Technology (Caltech).
Titled "Apparatus and Method for Automated Monitoring of Bacterial Spores," the invention has been filed under USPTO number US 7,563,615 B2 and describes an apparatus and method for automated monitoring of airborne bacterial spores.
"Universal Detection Technology's second patent on its licensed technology is another step forward in providing critical counter-bioterrorism equipment to organizations in the public, commercial and private sectors," said Universal Detection Technology CEO Jacques Tizabi. "This distinction will allow us to continue to bolster our intellectual property rights in the
The granted patent supplements the patent granted to the company in 2007 by providing intellectual property rights for the automated detection of airborne bacterial spores. Universal Detection Technology's BSM-2000 utilizes both technologies in its monitoring of airborne hazards.
The apparatus is provided with an air sampler, a surface for capturing bacterial spores, a source of lanthanide ions, and a spectrometer for excitation and detection of the characteristic fluorescence of the aromatic molecules in bacterial spores complexed with lanthanide ions. In accordance with the method, computer-programmed steps allow for automation of the apparatus for the monitoring of airborne bacterial spores.
TORREYPINES THERAPEUTICS INCORPORATED (NASDAQ: TPTX)
"Up 102.02% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/TPTX.php
TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates.
TPTX News:
July 27 - Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations
Raptor Pharmaceuticals Corp. (OTCBB: RPTP) ("Raptor" or the "Company") and TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) ("TorreyPines") announced that they have entered into a definitive merger agreement. Upon closing, the merger will result in a Nasdaq-listed biopharmaceutical company with a pipeline of mid- to late-stage clinical development candidates and preclinical drug targeting platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations. It is anticipated that the merged company will be named Raptor Pharmaceuticals Corp. and be headquartered in
Under terms of the agreement, which were unanimously approved by the boards of directors of Raptor and TorreyPines, upon closing, Raptor will be merged with and into a wholly-owned subsidiary of TorreyPines. TorreyPines will issue, and Raptor stockholders will receive shares of TorreyPines common stock such that Raptor stockholders will own approximately 95% and TorreyPines stockholders will own approximately 5% of the combined company. In addition, at closing, TorreyPines will implement a reverse stock split to ensure compliance with Nasdaq listing requirements; the exact size will be determined at closing. Closing of the merger is subject to customary conditions and contingent upon a vote of approval by both TorreyPines' and Raptor's stockholders at their respective annual meetings of stockholders, expected to take place in the fourth quarter of 2009.
In connection with the merger described herein, TorreyPines expects to file a registration statement on Form S-4, which shall include a joint proxy statement/prospectus, with the U.S. Securities Exchange Commission ("SEC") and any other necessary regulatory filings. Depending on the review process of the regulatory agencies, the companies currently expect the merger to close in the fourth quarter of 2009. Upon closing the transaction, the combined company's shares are expected to trade on the Nasdaq Capital Market. TorreyPines is advised by Merriman Curhan Ford and Raptor is advised by Beal Advisors.
The combined company will be dedicated to addressing unmet medical needs and underserved patient populations, by developing new or improving existing treatments, through enhanced drug targeting or reformulation of existing therapeutic compounds.
Management and Organization
Following the closing, the combined company will have offices in
* Christopher M. Starr, Ph.D., Chief Executive Officer
* Ted Daley, President
* Patrice Rioux, M.D., Ph.D., Chief Medical Officer
* Todd C. Zankel, Ph.D., Chief Scientific Officer
* Kim R. Tsuchimoto, C.P.A., Chief Financial Officer
Investors and security holders of Raptor and TorreyPines are urged to read the joint proxy statement/prospectus to be included in a registration statement filed on Form S-4 (including any amendments or supplements thereto) regarding the merger when it becomes available because it will contain important information about Raptor and TorreyPines.
MODERN TECHNOLOGY CORPORATION (OTC: MODC)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/MODC.php
MODC acquires promising technology companies and related assets to promote their growth and development. The company provides interim management and related services to its portfolio and client companies. It builds revenues and asset value through a model of continuous growth and derives further income from appreciation of its portfolio and licensing or revenue-sharing agreements.
MODC News:
July 28 - Modern Technology Corp Announces Emissions Controlled Green Fuel Power Generators
announced the latest product development arising from the Company's hydrogen generator and emission control technology. Beginning on 15 August 2009 worldwide shipping will begin for the Company's GreenGen de-centralized electricity generator systems.
The GreenGen systems feature multi-fuel capabilities allowing the use of diesel, bio-diesel, vegetable oils and even waste motor oils and transmission fluid. The systems are ideal for efficient green power production where high-reliability and extreme life/duty-cycles are required. The GreenGen system can run continuously on reclaimed, waste, and green fuels. GreenGen systems operate at an incredible 80%+ mechanical efficiency.
The GreenGen system employs the Company's EC-1 Emissions Control technology to reduce or eliminate exhaust emissions. The Company is not aware of any system possessing the GreenGen's combination of fuel efficiency, multi-fuel capability, emissions control, and extreme reliability.
GreenGen systems operate slowly between 600 and 1000 rpm. Higher rpm's create more noise pollution with most competitor systems operating at over 2400 rpm. Low rpm's insure long duty and life cycles. A GreenGen system can provide service for many decades.
GreenGen systems are available in power levels up to 24hp in 120 or 240 volts output.
GreenGen systems are startlingly fuel-efficient and use green or waste-product fuels. The entry-level 4 Kilowatt system uses approximately 2 gallons of fuel in 10 hours when running near full load. Single systems can be configured up to 24kw and can be combined to produce kilowatts above 24kw.
The anticipated market is international and includes commercial and residential level customers.
The Company is now capable of providing complete decentralized power station solutions with extreme reliability and life-cycles, operating solely on green-fuels with minimal or no emissions.
Investors will soon be further updated on the following:
* Improved online order entry and shipping application to handle distributors and customer orders.
* New distributor and applications for the OEM EC-1 for Electrical Power Generation using multi-fuel.
* New Emissions control target markets and international partners for distribution.
* Licensing agreements for OEM emission and fuel efficiency enhancements for bio-fuel generators.
* New product manufacturing and shipping facilities will be announced.
* Anticipated additional portfolio acquisitions adding revenues of $5-15 million dollars.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services.
